Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
Conditions
Keywords
CT-P13, Inflectra, Remicade, Infliximab, Observational, Follow-up, Safety, Effectiveness
Brief summary
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment. CT-P13 (brand names Inflectra and Remsima) is a biosimilar medicine to Remicade, meaning it is a biologic medicine that contains the same active substance as Remicade (infliximab). The key study objectives are as follows: * To characterize the population and drug utilization patterns of patients treated with CT-P13 for Crohn's Disease (CD) or Ulcerative Colitis (UC) in the context of standard of care Remicade * To explore the long-term safety profile of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade * To assess the effectiveness of CT-P13 in the treatment of patients with CD or UC in the context of standard of care Remicade
Detailed description
The study will be conducted in accordance with legal and regulatory requirements with scientific purpose, value and rigor following generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP), Good Epidemiological Practice (GEP), Good Practices for Outcomes Research, International Ethical Guidelines for Epidemiological Research, European Medicines Agency (EMA) European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology, and FDA Guidance for Industry. Data sources will be validated and will consist of the hospital medical records and monitoring will be organized on a regular basis. Data for the study will be entered into a web based electronic data capture (EDC) system at enrolment and then approximately every 3 months (at a minimum) thereafter up to 2 years. Adverse events will be encoded according to MedDRA 17.1 or later. The sample size will be approximately 2500 patients recruited over a 30 month period and followed up to 2 years. No inferential analyses are planned. Statistical analysis will be descriptive in nature.
Sponsors
Hospira, now a wholly owned subsidiary of Pfizer
Pfizer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. At least 12 years of age at the time of initial confirmed diagnosis of CD or UC and at least 18 years of age at the time of enrolment to the study. 2. Patients who are prescribed CT-P13 or Remicade for the treatment of CD or UC prescribed according to the corresponding summary of product characteristics (SmPC) as determined by the Investigator. Patients with stomas or surgery/pouch will be included.
Exclusion criteria
1. Any reported contraindications for CT-P13 or Remicade, according to the SmPC. 2. Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment. 3. Prior history of failure to respond to Remicade or CT-P13.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease Characteristics of Participants: Disease Duration | Baseline (Day 1) | Disease duration was defined as the number of months from initial diagnosis of inflammatory bowel disease (CD or UC) to the date of informed consent, which was recorded at the time of enrollment into the study (baseline). |
| Number of Participants Who Switched Treatment | From baseline to follow-up period (up to a maximum duration of 2 years) | Here, number of participants with either UC or CD, who switched from remicade to CT-P13; switched from CT-P13 to remicade and multiple switchers were reported. |
| Reasons for Switching Treatment by Participants | From baseline to follow-up period (up to a maximum duration of 2 years) | — |
| Total Dose of Infusion Received | From baseline to follow-up period (up to a maximum duration of 2 years) | Total dose of infusion received by the participants was calculated. |
| Number of Participants by Frequency of Infusion Received | Baseline (Day 1) | Number of participants by infusion frequency (weeks) were reported at baseline and categorized as follows: once a week; once every 2 weeks; once every 3 weeks; once every 4 weeks; once every 5 weeks; once every 6 weeks; once every 7 weeks; once every 8 weeks and others. Here, 'Others' category included all the frequencies apart from the mentioned categories. |
| Number of Participants Who Had Change in Infusion Dose | From baseline to follow-up period (up to a maximum duration of 2 years) | Participants who had change in the dose of infusion (either dose reduction or increase in dose) were included and reported. |
| Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | From baseline to follow-up period (up to a maximum duration of 2 years) | Participants who had change in infusion dose due to various reasons such as principal investigator's decision, participant's decisions, loss of response, lack of compliance, hypersensitivity, occurrence of adverse event (including adverse event special interest \[AESI\]/ serious adverse event \[SAE\]), positive for antibodies and other were reported. Here, 'Others' category included all reasons apart from the mentioned categories. A participant could have different reasons of dose change across visits, hence could be counted in more than one category. |
| Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC) | From baseline to follow-up period (up to a maximum duration of 2 years) | — |
| Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | From baseline to follow-up period (up to a maximum duration of 2 years) | An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent were events between first dose of infusion up to month 24, that were absent before treatment or that worsened relative to pretreatment state. Hypersensitivity was the pre-defined TEAE of special Interest for this study. AEs included both serious and non-serious adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline, Months 6, 12, 18 and 24 | The Montreal classification index for UC was used to classify the extent and severity of the disease activity. UC can be classified broadly into four disease activity/severity categories: Severity 0 (S0) = asymptomatic clinical remission; Severity 1 (S1) = Mild UC (passage of four or fewer stools/day \[with or without blood\], absence of any systemic illness, and normal inflammatory markers); Severity 2 (S2) = Moderate UC (passage of more than four stools per day but with minimal signs of systemic toxicity) and Severity 3 (S3) = Severe UC (passage of at least six bloody stools daily). |
| Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline, Months 6, 12, 18 and 24 | The fistula drainage assessment index was used to assess the improvement or remission of the disease activity of Crohn's Disease, based on 6 categories: remission (remission was defined as closure of all fistulae that were draining at baseline for at least two consecutive visits); improvement (improvement defined as a decrease from baseline in the number of open draining fistulae of 50% for at least two consecutive visits); worsened; unchanged; not accessible and missing disease activity. |
| Number of Participants Remaining in Clinical Remission or Relapse | Months 6, 12, 18 and 24 | Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point. Mayo score is an instrument designed to measure disease activity. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician's global assessment, each sub score graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease. The relapse of clinical remission was defined as the time from the date of first attaining CR to the date of relapse or death from any cause, whichever occurred first. |
| Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Baseline, Months 6, 12, 18, and 24 | Here, the laboratory tests related to the treatment or assessment of Crohn's Disease or Ulcerative Colitis was fecal calprotectin. |
| Number of Participants With Imaging Test Results | From baseline up to follow-up period (a maximum of 2 years) | Number of participants who had Imaging test results related to the treatment or assessment of Crohn's Disease or Ulcerative Colitis were reported. |
| Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Baseline, Months 6, 12, 18 and 24 | C-reactive protein (CRP) was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. A decrease in the level of CRP indicated reduction in inflammation and therefore improvement. |
| Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline, Months 6, 12, 18 and 24 | HBI is a simple index of CD activity. HBI measures 5 parameters; the general well-being (ranging from 0=very well to 4=terrible), abdominal pain ranging from 0 (none) to 3 (severe), number of liquid stools per day (no maximum score), presence of an abdominal mass on physical exam ranging from 0 (none) to 3 (definite and tender), and whether there are any complications ranging from 0=no complications, 1=Arthralgia; 2=Uveitis; 3=Erythema nodosum; 4=Aphthous ulcer; 5=Pyoderma gangrenosum; 6=Anal fissure; 7=New fistula and 8=abscess). The total HBI score is the sum of all the 5 individual parameters, the minimum score is 0 and there was no pre-specified maximum score as it depends on the number of liquids stools. Higher HBI scores=greater disease activity. The level of disease activity was interpreted as clinical remission (CR) (score less than \[\<\] 5), mild disease (MD) (score equal to \[=\] 5 to 7), moderate disease (Mod D) (score=8 to 16) and severe disease (SD) (score more than \[\>\] 16). |
| Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline, Months 6, 12, 18 and 24 | HBI is a simple index of CD activity. HBI measures 5 clinical parameters; the general well-being ranging from 0 (very well) to 4 (terrible), abdominal pain ranging from 0 (none) to 3 (severe), number of liquid stools per day (no maximum score), presence of an abdominal mass on physical exam ranging from 0 (none) to 3 (definite and tender), and whether there are any complications ranging from 0=no complications, 1=Arthralgia; 2=Uveitis; 3=Erythema nodosum; 4=Aphthous ulcer; 5=Pyoderma gangrenosum; 6=Anal fissure; 7=New fistula and 8=abscess). The total HBI score is the sum of all the 5 individual parameters, the minimum score is 0 and there was no pre-specified maximum score as it depends on the number of liquids stools. Higher HBI scores=greater disease activity. The level of disease activity was interpreted as clinical remission (CR) (HBI score \< 5), mild disease (MD) (HBI score = 5 to 7), moderate disease (Mod D) (HBI score = 8 to 16) and severe disease (SD) (HBI score \>16). |
| Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline, Months 6, 12, 18 and 24 | Mayo Score is an instrument to measure disease activity of UC. Score ranges from 0 to 12 points. It consists of 4 sub scores, each graded from 0 to 3. Higher scores = more severe disease. A Partial Mayo Score (PMS) (Mayo score without endoscopy) is comprised of 3 parameters: stool frequency ranging from 0 (normal number of stools) to 3 (having \>=5 stools more than normal), the presence of rectal bleeding (ranging from 0=no blood seen to 3=blood alone passes), and physician's global assessment (ranging from 0=normal to 3=severe disease). The total partial Mayo score was the sum of all the parameters, score ranging from 0 (normal or inactive disease) to 9 (severe disease). Higher scores indicated more severe disease. The score was calculated if data were available for at least 1 of 3 Mayo sub scores. The level of disease activity was interpreted as clinical remission (CR) (PMS \<2), mild disease (MD) (PMS=2 to 4), moderate disease (Mod D) (PMS=5 to 6) and severe disease (SD) (PMS \>6). |
| Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline, Months 6, 12, 18 and 24 | Mayo Score is an instrument to measure disease activity of UC. Score ranges from 0 to 12 points. It consists of 4 sub scores, each graded from 0 to 3. Higher scores= more severe disease. A Partial Mayo Score (PMS) (Mayo score without endoscopy) is comprised of 3 parameters: stool frequency ranging from 0 (normal number of stools) to 3 (having \>=5 stools more than normal), the presence of rectal bleeding ranging from 0 (no blood seen) to 3 (blood alone passes), and physician's global assessment ranging from 0 (normal) to 3 (severe disease). The total partial Mayo score was the sum of all the parameters, score ranging from 0 (normal or inactive disease) to 9 (severe disease). Higher scores indicated more severe disease. The score was calculated if data were available for at least 1 of 3 Mayo sub scores. The level of disease activity was interpreted as clinical remission (CR) (PMS \<2), mild disease (MD) (PMS=2 to 4), moderate disease (Mod D) (PMS=5 to 6) and severe disease (SD) (PMS \>6). |
| Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | At Baseline | The Montreal classification index for CD was used to classify the extent of the disease activity. It consisted of three parameters: age at diagnosis, location and behavior of the disease activity. There were four different age groups categorized: 16 years or younger, 17-40 years, over 40 years and missing. |
| Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Baseline, Months 6, 12, 18 and 24 | The Montreal classification index for CD was used to classify the extent of the disease activity. It consisted of three parameters: age at diagnosis, location and behavior of the disease activity. There are four different disease locations presented: Location 1 (L1) is terminal ileum, Location 2 (L2) is colon, Location 3 (L3) is ileocolon and Location 4 (L4) is upper gastrointestinal (GI). The first three categories (L1-L3) was combined with L4 where disease sites coexisted. |
| Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Baseline, Months 6, 12, 18 and 24 | The Montreal classification index for CD was used to classify the extent of the disease activity. It consists of two parameters: location and behavior of the disease activity. There were 4 different categories for the behavior of the disease activity: Behaviour 1 (B1) was nonstricturing (NS), nonpenetrating (NP); Behaviour 2 (B2) was structuring; Behaviour 3 (B3) was penetrating and p as perianal disease (p). The first 3 categories (B1 to B3) could be added with p to indicate coexisting perianal disease. Perianal disease (p) was defined as the presence of perianal abscesses or fistulae. |
| Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline, Months 6, 12, 18 and 24 | The Montreal classification index for Ulcerative Colitis (UC) was used to classify the extent and severity of the disease activity. There were three subgroups of UC defined by extent: Extent 1 (E1) =Ulcerative proctitis, Extent 2 (E2) =Left-sided UC and Extent 3 (E3) =Extensive UC. |
Countries
Belgium, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Portugal, Slovakia, Spain, United Kingdom
Participant flow
Pre-assignment details
A total of 2565 participants were enrolled in the study, out of which 22 participants were not eligible to receive treatment for any of the treatment groups. Hence, only those participants who received treatment during the study observation period were included in the participants flow section.
Participants by arm
| Arm | Count |
|---|---|
| CT-P13 Participants diagnosed with either Crohn's Disease (CD) or Ulcerative Colitis (UC), and who were biologic naive initiating CT-P13 and received CT-P13 continuously, or participants who were treated with CT-P13 continuously, or who were treated with CT-P13 then switched to other anti-tumor necrosis factors (TNFs) therapy except Remicade or non-biologic treatment during the study, or those who switched to CT-P13 from an alternative biologic therapy (except Remicade) due to non-responsiveness to or intolerance with existing therapy were enrolled in this group. Participants received CT-P13 continuously in accordance with usual clinical practice of Inflammatory bowel disease (IBD) at the discretion of the physician and observed for a duration of approximately 24 months. | 1,522 |
| Remicade Participants diagnosed with either CD or UC, and who were biologic naive initiating Remicade and received Remicade continuously, or participants who were treated with Remicade continuously, or who were treated with Remicade then switched to other anti-TNFs therapy (except CT-P13) or non-biologic treatment during the study, or those who switched to Remicade from an alternative biologic therapy (except CT-P13) due to non-responsiveness or intolerance were enrolled in this group. Participants received Remicade in accordance with usual clinical practice of IBD at the discretion of the physician and observed for a duration of approximately 24 months. | 494 |
| Switched From Remicade to CT-P13 Participants diagnosed with either CD or UC and who were previously treated with Remicade continuously as per usual clinical practice of IBD, switched to CT-P13 once, either at enrollment or during the study were observed for a duration of approximately 24 months. | 358 |
| Switched From CT-P13 to Remicade Participants diagnosed with either CD or UC and who were previously treated with CT-P13 continuously as per usual clinical practice of IBD, switched to Remicade once, either at enrollment or during the study were observed for a duration of approximately 24 months. | 67 |
| Multiple Switchers Participants with CD or UC with at least 2 switches between Remicade and CT-P13 during the study, were observed for a duration of approximately 24 months. Both Remicade and CT-P13 were administered as per usual clinical practice of IBD. | 102 |
| Total | 2,543 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 44 | 5 | 9 | 0 | 3 |
| Overall Study | Death | 4 | 2 | 1 | 0 | 0 |
| Overall Study | Lost to Follow-up | 96 | 21 | 16 | 4 | 3 |
| Overall Study | Missing | 10 | 3 | 0 | 0 | 0 |
| Overall Study | Other | 145 | 18 | 24 | 1 | 3 |
| Overall Study | Participant Non-compliant | 13 | 2 | 1 | 1 | 0 |
| Overall Study | Physician Decision | 49 | 15 | 7 | 0 | 2 |
| Overall Study | Withdrawal by Subject | 44 | 35 | 9 | 1 | 3 |
Baseline characteristics
| Characteristic | Remicade | Total | CT-P13 | Multiple Switchers | Switched From CT-P13 to Remicade | Switched From Remicade to CT-P13 |
|---|---|---|---|---|---|---|
| Age, Continuous | 38.8 years STANDARD_DEVIATION 12.74 | 39.8 years STANDARD_DEVIATION 13.74 | 39.8 years STANDARD_DEVIATION 14.65 | 38.4 years STANDARD_DEVIATION 13.23 | 41.1 years STANDARD_DEVIATION 13.96 | 40.9 years STANDARD_DEVIATION 14.14 |
| Participants With a History of Cancer | 10 Participants | 62 Participants | 41 Participants | 4 Participants | 1 Participants | 6 Participants |
| Participants With a History of Fistula Disease | 124 Participants | 561 Participants | 304 Participants | 28 Participants | 19 Participants | 86 Participants |
| Participants With a History Surgery | 165 Participants | 731 Participants | 395 Participants | 32 Participants | 23 Participants | 116 Participants |
| Participants With Medical History of Smoking | 94 Participants | 513 Participants | 320 Participants | 17 Participants | 12 Participants | 70 Participants |
| Participants With Stoma Status | 13 Participants | 65 Participants | 33 Participants | 2 Participants | 3 Participants | 14 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 Participants | 5 Participants | 4 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 3 Participants | 13 Participants | 5 Participants | 0 Participants | 0 Participants | 5 Participants |
| Race/Ethnicity, Customized Black or African American | 0 Participants | 8 Participants | 7 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other | 60 Participants | 401 Participants | 267 Participants | 14 Participants | 11 Participants | 49 Participants |
| Race/Ethnicity, Customized Unknown or Not Reported | 39 Participants | 231 Participants | 158 Participants | 5 Participants | 1 Participants | 28 Participants |
| Race/Ethnicity, Customized White | 391 Participants | 1884 Participants | 1080 Participants | 83 Participants | 55 Participants | 275 Participants |
| Sex: Female, Male Female | 233 Participants | 1218 Participants | 750 Participants | 48 Participants | 29 Participants | 158 Participants |
| Sex: Female, Male Male | 261 Participants | 1325 Participants | 772 Participants | 54 Participants | 38 Participants | 200 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 1,522 | 2 / 494 | 1 / 358 | 0 / 67 | 0 / 102 |
| other Total, other adverse events | 442 / 1,522 | 100 / 494 | 90 / 358 | 7 / 67 | 21 / 102 |
| serious Total, serious adverse events | 256 / 1,522 | 43 / 494 | 57 / 358 | 10 / 67 | 15 / 102 |
Outcome results
Primary
Disease Characteristics of Participants: Disease Duration
Disease duration was defined as the number of months from initial diagnosis of inflammatory bowel disease (CD or UC) to the date of informed consent, which was recorded at the time of enrollment into the study (baseline).
Time frame: Baseline (Day 1)
Population: Safety analysis population included all participants who received at least 1 dose of study drug during the observation period. Here, 'Overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CT-P13 | Disease Characteristics of Participants: Disease Duration | 63.0 months |
| Remicade | Disease Characteristics of Participants: Disease Duration | 112.5 months |
| Switched From Remicade to CT-P13 | Disease Characteristics of Participants: Disease Duration | 120.0 months |
| Switched From CT-P13 to Remicade | Disease Characteristics of Participants: Disease Duration | 86.0 months |
| Multiple Switchers | Disease Characteristics of Participants: Disease Duration | 101.0 months |
Primary
Number of Participants by Frequency of Infusion Received
Number of participants by infusion frequency (weeks) were reported at baseline and categorized as follows: once a week; once every 2 weeks; once every 3 weeks; once every 4 weeks; once every 5 weeks; once every 6 weeks; once every 7 weeks; once every 8 weeks and others. Here, 'Others' category included all the frequencies apart from the mentioned categories.
Time frame: Baseline (Day 1)
Population: Safety analysis population included all participants who received at least 1 dose of study drug during the observation period. Here, 'Overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Number of Participants by Frequency of Infusion Received | Other | 124 Participants |
| CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 5 weeks | 7 Participants |
| CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 2 weeks | 140 Participants |
| CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 6 weeks | 84 Participants |
| CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 8 weeks | 804 Participants |
| CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 3 weeks | 1 Participants |
| CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 7 weeks | 9 Participants |
| CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 4 weeks | 109 Participants |
| CT-P13 | Number of Participants by Frequency of Infusion Received | Once a week | 5 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Once every 7 weeks | 27 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Once every 6 weeks | 67 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Once every 4 weeks | 47 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Once every 5 weeks | 8 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Once every 3 weeks | 0 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Other | 32 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Once every 2 weeks | 5 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Once a week | 0 Participants |
| Remicade | Number of Participants by Frequency of Infusion Received | Once every 8 weeks | 247 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 6 weeks | 43 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Once a week | 0 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 2 weeks | 11 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 3 weeks | 0 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 4 weeks | 32 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 5 weeks | 5 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 7 weeks | 14 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Once every 8 weeks | 198 Participants |
| Switched From Remicade to CT-P13 | Number of Participants by Frequency of Infusion Received | Other | 14 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Once every 4 weeks | 9 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Once every 6 weeks | 3 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Once every 3 weeks | 0 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Once every 7 weeks | 2 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Once every 2 weeks | 3 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Other | 1 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Once every 8 weeks | 42 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Once a week | 0 Participants |
| Switched From CT-P13 to Remicade | Number of Participants by Frequency of Infusion Received | Once every 5 weeks | 0 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Once a week | 0 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Once every 4 weeks | 7 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Once every 6 weeks | 15 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Once every 3 weeks | 1 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Once every 5 weeks | 4 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Other | 4 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Once every 8 weeks | 47 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Once every 7 weeks | 4 Participants |
| Multiple Switchers | Number of Participants by Frequency of Infusion Received | Once every 2 weeks | 3 Participants |
Primary
Number of Participants Who Had Change in Infusion Dose
Participants who had change in the dose of infusion (either dose reduction or increase in dose) were included and reported.
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Population: Safety analysis population included all participants who received at least 1 dose of study drug during the observation period.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CT-P13 | Number of Participants Who Had Change in Infusion Dose | 479 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose | 110 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose | 89 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose | 28 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose | 31 Participants |
Primary
Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change
Participants who had change in infusion dose due to various reasons such as principal investigator's decision, participant's decisions, loss of response, lack of compliance, hypersensitivity, occurrence of adverse event (including adverse event special interest \[AESI\]/ serious adverse event \[SAE\]), positive for antibodies and other were reported. Here, 'Others' category included all reasons apart from the mentioned categories. A participant could have different reasons of dose change across visits, hence could be counted in more than one category.
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Population: Safety analysis population included all participants who received at least 1 dose of study drug during the observation period. Here, 'Overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Principal Investigator's Decision | 213 Participants |
| CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Participant's Decision | 5 Participants |
| CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Loss of response | 142 Participants |
| CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Lack of compliance | 3 Participants |
| CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Hypersensitivity | 4 Participants |
| CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Occurrence of Adverse Event (including AESI/SAE) | 23 Participants |
| CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Other | 142 Participants |
| CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Positive for antibodies | 5 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Lack of compliance | 1 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Positive for antibodies | 2 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Participant's Decision | 2 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Principal Investigator's Decision | 61 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Loss of response | 27 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Hypersensitivity | 1 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Other | 26 Participants |
| Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Occurrence of Adverse Event (including AESI/SAE) | 3 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Loss of response | 17 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Positive for antibodies | 2 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Participant's Decision | 0 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Principal Investigator's Decision | 31 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Occurrence of Adverse Event (including AESI/SAE) | 3 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Lack of compliance | 0 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Hypersensitivity | 1 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Other | 42 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Participant's Decision | 0 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Loss of response | 3 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Lack of compliance | 0 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Occurrence of Adverse Event (including AESI/SAE) | 0 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Hypersensitivity | 0 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Positive for antibodies | 0 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Principal Investigator's Decision | 26 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Other | 2 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Hypersensitivity | 0 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Lack of compliance | 0 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Loss of response | 12 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Other | 9 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Principal Investigator's Decision | 16 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Participant's Decision | 0 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Positive for antibodies | 0 Participants |
| Multiple Switchers | Number of Participants Who Had Change in Infusion Dose Categorized Based on Reasons of Change | Occurrence of Adverse Event (including AESI/SAE) | 2 Participants |
Primary
Number of Participants Who Switched Treatment
Here, number of participants with either UC or CD, who switched from remicade to CT-P13; switched from CT-P13 to remicade and multiple switchers were reported.
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Population: Safety analysis population included all participants who received at least 1 dose of study drug during the observation period.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Number of Participants Who Switched Treatment | Crohn's Disease | 237 Participants |
| CT-P13 | Number of Participants Who Switched Treatment | Ulcerative Colitis | 121 Participants |
| Remicade | Number of Participants Who Switched Treatment | Crohn's Disease | 47 Participants |
| Remicade | Number of Participants Who Switched Treatment | Ulcerative Colitis | 20 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Switched Treatment | Crohn's Disease | 72 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Switched Treatment | Ulcerative Colitis | 30 Participants |
Primary
Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC)
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Population: Safety analysis population included all participants who received at least 1 dose of study drug during the observation period.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CT-P13 | Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC) | 1025 Participants |
| Remicade | Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC) | 262 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC) | 187 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC) | 39 Participants |
| Multiple Switchers | Number of Participants Who Took Concomitant Medications Related to the Treatment of Crohn's Disease (CD) or Ulcerative Colitis (UC) | 67 Participants |
Primary
Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent were events between first dose of infusion up to month 24, that were absent before treatment or that worsened relative to pretreatment state. Hypersensitivity was the pre-defined TEAE of special Interest for this study. AEs included both serious and non-serious adverse events.
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Population: Safety analysis population included all participants who received at least 1 dose of study drug during the observation period.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs of Special Interest | 189 Participants |
| CT-P13 | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | SAEs | 256 Participants |
| CT-P13 | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs | 621 Participants |
| Remicade | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | SAEs | 43 Participants |
| Remicade | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs of Special Interest | 49 Participants |
| Remicade | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs | 133 Participants |
| Switched From Remicade to CT-P13 | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs | 130 Participants |
| Switched From Remicade to CT-P13 | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | SAEs | 57 Participants |
| Switched From Remicade to CT-P13 | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs of Special Interest | 37 Participants |
| Switched From CT-P13 to Remicade | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | SAEs | 10 Participants |
| Switched From CT-P13 to Remicade | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs | 15 Participants |
| Switched From CT-P13 to Remicade | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs of Special Interest | 8 Participants |
| Multiple Switchers | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs of Special Interest | 11 Participants |
| Multiple Switchers | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | SAEs | 15 Participants |
| Multiple Switchers | Number of Participants With Treatment-Emergent Adverse Event (AEs), Serious Adverse Events (SAEs) and Adverse Event With Special Interest (AESIs) | TEAEs | 30 Participants |
Primary
Reasons for Switching Treatment by Participants
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Population: Reasons for switch were not captured in electronic data capture. Hence, due to change in planned analysis, data was not collected and analyzed.
Primary
Total Dose of Infusion Received
Total dose of infusion received by the participants was calculated.
Time frame: From baseline to follow-up period (up to a maximum duration of 2 years)
Population: Safety analysis population included all participants who received at least 1 dose of study drug during the observation period. Here, 'Overall number of participants analyzed' signifies number of participants evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| CT-P13 | Total Dose of Infusion Received | NA milligram |
| Remicade | Total Dose of Infusion Received | NA milligram |
| Switched From Remicade to CT-P13 | Total Dose of Infusion Received | NA milligram |
| Switched From CT-P13 to Remicade | Total Dose of Infusion Received | NA milligram |
| Multiple Switchers | Total Dose of Infusion Received | NA milligram |
Secondary
Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index
The fistula drainage assessment index was used to assess the improvement or remission of the disease activity of Crohn's Disease, based on 6 categories: remission (remission was defined as closure of all fistulae that were draining at baseline for at least two consecutive visits); improvement (improvement defined as a decrease from baseline in the number of open draining fistulae of 50% for at least two consecutive visits); worsened; unchanged; not accessible and missing disease activity.
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Remission | 50 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Missing | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Improvement | 39 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Not accessible | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Worsened | 9 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Unchanged | 8 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Unchanged | 20 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Unchanged | 19 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Missing | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Worsened | 3 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Not accessible | 4 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Improvement | 90 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Improvement | 8 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Missing | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Remission | 16 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Remission | 65 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Missing | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Improvement | 62 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Not accessible | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Worsened | 12 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Not accessible | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Unchanged | 15 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Unchanged | 21 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Worsened | 9 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Worsened | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Not accessible | 4 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Improvement | 23 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Missing | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Remission | 64 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Remission | 36 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Worsened | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Remission | 23 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Remission | 29 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Remission | 30 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Improvement | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Unchanged | 3 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Not accessible | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Unchanged | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Worsened | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Improvement | 4 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Unchanged | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Improvement | 23 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Not accessible | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Unchanged | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Not accessible | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Worsened | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Worsened | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Not accessible | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Worsened | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Improvement | 6 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Remission | 16 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Unchanged | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Improvement | 26 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Remission | 12 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Not accessible | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Remission | 14 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Improvement | 5 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Worsened | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Unchanged | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Not accessible | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Remission | 17 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Improvement | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Worsened | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Unchanged | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Not accessible | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Remission | 11 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Improvement | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Worsened | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Unchanged | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Not accessible | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Remission | 9 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Improvement | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Worsened | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Unchanged | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Not accessible | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Remission | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Improvement | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Worsened | 2 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Unchanged | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Not accessible | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Remission | 6 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Improvement | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Remission | 7 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Worsened | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Improvement | 11 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Not accessible | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Unchanged | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Improvement | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Unchanged | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Unchanged | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Remission | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Worsened | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Improvement | 9 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Worsened | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Not accessible | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Unchanged | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Unchanged | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Not accessible | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Improvement | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Worsened | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Not accessible | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Remission | 6 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Not accessible | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Remission | 9 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Worsened | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Remission | 8 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Not accessible | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Unchanged | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Improvement | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Unchanged | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Improvement | 4 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Worsened | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Worsened | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Unchanged | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Improvement | 4 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Not accessible | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Remission | 8 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 18 | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Not accessible | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Remission | 7 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Not accessible | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Remission | 6 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Improvement | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Unchanged | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Worsened | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Worsened | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Baseline | Worsened | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Unchanged | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Improvement | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Not accessible | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 12 | Remission | 9 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 24 | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Fistula Drainage Assessment Index | Month 6 | Missing | 0 Participants |
Secondary
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis
The Montreal classification index for CD was used to classify the extent of the disease activity. It consisted of three parameters: age at diagnosis, location and behavior of the disease activity. There were four different age groups categorized: 16 years or younger, 17-40 years, over 40 years and missing.
Time frame: At Baseline
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified rows for each arm.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 16 years or younger | 61 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 17-40 years | 553 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Over 40 years | 162 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Missing | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 16 years or younger | 33 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 17-40 years | 174 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Over 40 years | 33 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 17-40 years | 115 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Over 40 years | 28 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 16 years or younger | 21 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 16 years or younger | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 17-40 years | 25 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Over 40 years | 8 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | Over 40 years | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 17-40 years | 39 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Age at Diagnosis | 16 years or younger | 6 Participants |
Secondary
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity
The Montreal classification index for CD was used to classify the extent of the disease activity. It consists of two parameters: location and behavior of the disease activity. There were 4 different categories for the behavior of the disease activity: Behaviour 1 (B1) was nonstricturing (NS), nonpenetrating (NP); Behaviour 2 (B2) was structuring; Behaviour 3 (B3) was penetrating and p as perianal disease (p). The first 3 categories (B1 to B3) could be added with p to indicate coexisting perianal disease. Perianal disease (p) was defined as the presence of perianal abscesses or fistulae.
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS, NP | 242 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating | 84 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | Missing | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating, p Perianal disease | 42 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing | 122 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating, p Perianal disease | 15 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, p Perianal disease | 22 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS,NP, p Perianal disease | 64 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating | 64 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | p Perianal disease | 4 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | p Perianal disease | 27 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating | 18 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing | 47 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | p Perianal disease | 34 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS, NP | 77 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | Missing | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating, p Perianal disease | 27 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing | 165 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, p Perianal disease | 14 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS,NP, p Perianal disease | 40 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS,NP, p Perianal disease | 77 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | Missing | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | p Perianal disease | 10 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating | 26 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, p Perianal disease | 32 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS, NP | 324 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing | 77 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS, NP | 135 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | Missing | 3 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, p Perianal disease | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating, p Perianal disease | 33 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, p Perianal disease | 22 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating, p Perianal disease | 57 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS,NP, p Perianal disease | 23 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS,NP, p Perianal disease | 60 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | p Perianal disease | 17 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | Missing | 3 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating | 48 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing | 94 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS, NP | 191 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, p Perianal disease | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS, NP | 92 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing | 40 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating | 32 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | p Perianal disease | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS,NP, p Perianal disease | 33 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating, p Perianal disease | 30 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS, NP | 68 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing | 29 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating | 32 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | p Perianal disease | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS,NP, p Perianal disease | 34 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, p Perianal disease | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating, p Perianal disease | 29 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS, NP | 56 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing | 26 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating | 26 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | p Perianal disease | 7 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS,NP, p Perianal disease | 20 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, p Perianal disease | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating, p Perianal disease | 20 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS, NP | 44 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing | 24 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating | 16 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | p Perianal disease | 4 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS,NP, p Perianal disease | 15 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, p Perianal disease | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating, p Perianal disease | 20 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS, NP | 35 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | p Perianal disease | 3 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS,NP, p Perianal disease | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, p Perianal disease | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating, p Perianal disease | 12 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | p Perianal disease | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing | 43 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS, NP | 26 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating, p Perianal disease | 13 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, p Perianal disease | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating, p Perianal disease | 11 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing | 26 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing | 36 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, p Perianal disease | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating | 9 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing | 28 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS,NP, p Perianal disease | 11 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | p Perianal disease | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, p Perianal disease | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS,NP, p Perianal disease | 16 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating | 16 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS,NP, p Perianal disease | 11 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating, p Perianal disease | 12 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS,NP, p Perianal disease | 9 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | p Perianal disease | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS, NP | 66 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, p Perianal disease | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating | 14 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating | 12 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS,NP, p Perianal disease | 6 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS, NP | 46 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | p Perianal disease | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating, p Perianal disease | 11 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, p Perianal disease | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating, p Perianal disease | 10 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing | 15 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS, NP | 20 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS, NP | 40 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | p Perianal disease | 7 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS, NP | 10 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing | 6 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | p Perianal disease | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating, p Perianal disease | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing | 9 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS,NP, p Perianal disease | 6 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, p Perianal disease | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS,NP, p Perianal disease | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating, p Perianal disease | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, p Perianal disease | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS, NP | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS,NP, p Perianal disease | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, p Perianal disease | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | p Perianal disease | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS,NP, p Perianal disease | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, p Perianal disease | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating, p Perianal disease | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | p Perianal disease | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS, NP | 9 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS, NP | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating | 6 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | p Perianal disease | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing | 8 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS,NP, p Perianal disease | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating, p Perianal disease | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, p Perianal disease | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS, NP | 10 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | p Perianal disease | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating, p Perianal disease | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating, p Perianal disease | 6 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS,NP, p Perianal disease | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B1 NS, NP | 7 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating | 6 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS, NP | 14 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, p Perianal disease | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing | 9 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing | 9 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B3 Penetrating, p Perianal disease | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B3 Penetrating | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS, NP | 17 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | p Perianal disease | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing | 12 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B1 NS,NP, p Perianal disease | 6 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS, NP | 17 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B2 Stricturing | 13 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS,NP, p Perianal disease | 6 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B1 NS,NP, p Perianal disease | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing | 10 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B3 Penetrating, p Perianal disease | 4 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | p Perianal disease | 3 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | B1 NS,NP, p Perianal disease | 6 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 12: Behavior | p Perianal disease | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B3 Penetrating, p Perianal disease | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 6: Behavior | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 24: Behavior | B2 Stricturing, B3 Penetrating, p Perianal disease | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | B1 NS, NP | 13 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | At Baseline: Behavior | B3 Penetrating, p Perianal disease | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Behavior of the Disease Activity | Month 18: Behavior | Missing | 0 Participants |
Secondary
Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location
The Montreal classification index for CD was used to classify the extent of the disease activity. It consisted of three parameters: age at diagnosis, location and behavior of the disease activity. There are four different disease locations presented: Location 1 (L1) is terminal ileum, Location 2 (L2) is colon, Location 3 (L3) is ileocolon and Location 4 (L4) is upper gastrointestinal (GI). The first three categories (L1-L3) was combined with L4 where disease sites coexisted.
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum | 150 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum | 202 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon | 74 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L4 Upper GI | 14 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | Missing | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon, L4 Upper GI | 11 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon | 105 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon | 135 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon, L4 Upper GI | 3 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum, L4 Upper GI | 15 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L4 Upper GI | 8 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon | 236 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon, L4 Upper GI | 6 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L4 Upper GI | 12 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon | 329 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon | 150 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L4 Upper GI | 7 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum | 60 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum | 257 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon | 53 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon, L4 Upper GI | 14 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum, L4 Upper GI | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon | 41 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | Missing | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum | 99 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | Missing | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon, L4 Upper GI | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | Missing | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | Missing | 3 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon, L4 Upper GI | 8 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon, L4 Upper GI | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon, L4 Upper GI | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon, L4 Upper GI | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon, L4 Upper GI | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum, L4 Upper GI | 21 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum, L4 Upper GI | 11 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum, L4 Upper GI | 13 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L4 Upper GI | 10 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon | 200 Participants |
| CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon | 84 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon | 54 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum | 17 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon, L4 Upper GI | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon | 16 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon | 33 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L4 Upper GI | 6 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon, L4 Upper GI | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | Missing | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon, L4 Upper GI | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum | 49 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon | 47 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum | 62 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon | 94 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L4 Upper GI | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon | 107 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum, L4 Upper GI | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon, L4 Upper GI | 3 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon, L4 Upper GI | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum | 38 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L4 Upper GI | 4 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon | 40 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon | 71 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L4 Upper GI | 3 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum, L4 Upper GI | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon, L4 Upper GI | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum, L4 Upper GI | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon, L4 Upper GI | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum | 28 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon | 31 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon | 55 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L4 Upper GI | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon, L4 Upper GI | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon, L4 Upper GI | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon, L4 Upper GI | 4 Participants |
| Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum | 26 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon | 32 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon, L4 Upper GI | 12 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum | 22 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum | 15 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon | 20 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L4 Upper GI | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon | 55 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon, L4 Upper GI | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L4 Upper GI | 2 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum, L4 Upper GI | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon, L4 Upper GI | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon, L4 Upper GI | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum, L4 Upper GI | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon | 14 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum | 16 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon | 18 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L4 Upper GI | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon, L4 Upper GI | 7 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon | 40 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon | 65 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L4 Upper GI | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon | 22 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum, L4 Upper GI | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon | 80 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon | 25 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L4 Upper GI | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon, L4 Upper GI | 7 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum | 34 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon | 12 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon, L4 Upper GI | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum | 7 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L4 Upper GI | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon | 14 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon | 11 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L4 Upper GI | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon | 10 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L4 Upper GI | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum | 6 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon | 9 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum | 7 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon | 8 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon | 13 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon | 9 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon | 16 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L4 Upper GI | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon | 14 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum | 8 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum | 11 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon | 8 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon | 28 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L1 Terminal ileum, L4 Upper GI | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L2 Colon, L4 Upper GI | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | L3 Ileocolon, L4 Upper GI | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | At Baseline: Location | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum | 9 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon | 11 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon | 22 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | L3 Ileocolon, L4 Upper GI | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 6: Location | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum | 7 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon | 10 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon | 21 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L4 Upper GI | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | L3 Ileocolon, L4 Upper GI | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 12: Location | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon | 9 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon | 17 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L4 Upper GI | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | L3 Ileocolon, L4 Upper GI | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 18: Location | Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon | 5 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon | 14 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L4 Upper GI | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L1 Terminal ileum, L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L2 Colon, L4 Upper GI | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | L3 Ileocolon, L4 Upper GI | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants Categorized on the Basis of Montreal Classification Index by Location | Month 24: Location | Missing | 0 Participants |
Secondary
Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity
HBI is a simple index of CD activity. HBI measures 5 clinical parameters; the general well-being ranging from 0 (very well) to 4 (terrible), abdominal pain ranging from 0 (none) to 3 (severe), number of liquid stools per day (no maximum score), presence of an abdominal mass on physical exam ranging from 0 (none) to 3 (definite and tender), and whether there are any complications ranging from 0=no complications, 1=Arthralgia; 2=Uveitis; 3=Erythema nodosum; 4=Aphthous ulcer; 5=Pyoderma gangrenosum; 6=Anal fissure; 7=New fistula and 8=abscess). The total HBI score is the sum of all the 5 individual parameters, the minimum score is 0 and there was no pre-specified maximum score as it depends on the number of liquids stools. Higher HBI scores=greater disease activity. The level of disease activity was interpreted as clinical remission (CR) (HBI score \< 5), mild disease (MD) (HBI score = 5 to 7), moderate disease (Mod D) (HBI score = 8 to 16) and severe disease (SD) (HBI score \>16).
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-SD | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Mod D | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Missing | 13 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-CR | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-MD | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-MD | 15 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Missing | 61 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-MD | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-CR | 82 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-CR | 34 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 10 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Mod D | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-CR | 39 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-SD | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Missing | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-CR | 60 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Missing | 4 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Missing | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-MD | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-MD | 19 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Mod D | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Mod D | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-CR | 81 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: SD | 6 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-MD | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Mod D | 4 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-MD | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-MD | 16 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-CR | 23 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-MD | 30 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 25 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-CR | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Mod D | 7 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-CR | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Missing | 21 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Missing | 2 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Missing | 34 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-SD | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Missing | 85 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: Mod D | 91 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-SD | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Missing | 32 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Missing | 52 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: MD | 137 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 14 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-CR | 39 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-SD | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-CR | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Missing | 7 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-MD | 13 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-MD | 15 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Mod D | 12 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-MD | 10 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-CR | 30 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 16 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-CR | 21 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Mod D | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Missing | 13 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: Mod D | 22 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Missing | 5 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Missing | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Mod D | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-CR | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-MD | 6 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-MD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-CR | 24 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Mod D | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-SD | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: MD | 45 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Missing | 3 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-SD | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 9 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-CR | 4 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-MD | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-MD | 6 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-CR | 3 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: SD | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Missing | 25 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Missing | 4 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Mod D | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-MD | 6 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-CR | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-CR | 13 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-MD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Mod D | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 2 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-SD | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Missing | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-MD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Mod D | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-CR | 24 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-MD | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-MD | 6 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-CR | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Mod D | 6 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-MD | 13 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Missing | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Missing | 9 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-CR | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 3 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-CR | 6 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-MD | 7 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-MD | 9 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-CR | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: MD | 24 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: Mod D | 15 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-CR | 9 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-MD | 11 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Mod D | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-SD | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-CR | 6 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-MD | 2 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 6 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Missing | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-CR | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-MD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Mod D | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-CR | 14 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-MD | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Mod D | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Missing | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-CR | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-MD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 6 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Missing | 5 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-CR | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-MD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Mod D | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-CR | 12 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-MD | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Missing | 10 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-CR | 2 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-MD | 2 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Missing | 8 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-CR | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-MD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Mod D | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-CR | 8 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-MD | 2 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Missing | 13 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-CR | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-MD | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Missing | 7 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-CR | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-MD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-CR | 6 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-CR | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Missing | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: MD | 10 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-MD | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-MD | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: Mod D | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Missing | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Missing | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-CR | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-MD | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-CR | 5 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-MD | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-MD | 4 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-MD | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-MD | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Missing | 4 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: Mod D | 3 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-MD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-MD | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-CR | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-CR | 3 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-MD | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: MD | 7 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-SD | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-Mod D | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-CR | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 18-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-MD | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-CR | 3 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-CR | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 12-CR | 4 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-MD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-MD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-MD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 18-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-CR | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | At Baseline: SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-CR | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 6-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-MD | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Missing | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Mod D | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 24-Missing | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-MD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-CR | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 6-CR | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-MD | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-SD | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-MD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 6-Mod D | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-CR | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 12-CR | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-MD | 3 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Missing | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-Mod D | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-MD; Month 18-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index According to Disease Activity | Baseline-Mod D; Month 24-Missing | 1 Participants |
Secondary
Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission
HBI is a simple index of CD activity. HBI measures 5 parameters; the general well-being (ranging from 0=very well to 4=terrible), abdominal pain ranging from 0 (none) to 3 (severe), number of liquid stools per day (no maximum score), presence of an abdominal mass on physical exam ranging from 0 (none) to 3 (definite and tender), and whether there are any complications ranging from 0=no complications, 1=Arthralgia; 2=Uveitis; 3=Erythema nodosum; 4=Aphthous ulcer; 5=Pyoderma gangrenosum; 6=Anal fissure; 7=New fistula and 8=abscess). The total HBI score is the sum of all the 5 individual parameters, the minimum score is 0 and there was no pre-specified maximum score as it depends on the number of liquids stools. Higher HBI scores=greater disease activity. The level of disease activity was interpreted as clinical remission (CR) (score less than \[\<\] 5), mild disease (MD) (score equal to \[=\] 5 to 7), moderate disease (Mod D) (score=8 to 16) and severe disease (SD) (score more than \[\>\] 16).
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | At Baseline | 606 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-CR | 485 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-MD | 42 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-CR | 194 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Missing | 55 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-CR | 326 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Mod D | 5 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Missing | 247 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-CR | 429 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Mod D | 23 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Missing | 121 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Missing | 391 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-SD | 0 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-MD | 36 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-MD | 25 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-MD | 16 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-SD | 1 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Mod D | 8 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Mod D | 20 Participants |
| CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Mod D | 4 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-MD | 11 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-CR | 143 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Missing | 46 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-MD | 11 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Missing | 140 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Mod D | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Mod D | 8 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-MD | 7 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-SD | 1 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-CR | 98 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Missing | 15 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-CR | 211 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Missing | 88 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-CR | 182 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | At Baseline | 246 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-MD | 14 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Mod D | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Missing | 28 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | At Baseline | 150 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-CR | 125 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-MD | 11 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Mod D | 2 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Missing | 12 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-CR | 109 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-MD | 8 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Mod D | 5 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-CR | 96 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-MD | 4 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Mod D | 2 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Missing | 48 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-CR | 68 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-MD | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Mod D | 3 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-SD | 1 Participants |
| Switched From Remicade to CT-P13 | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Missing | 75 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-MD | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Mod D | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | At Baseline | 29 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-MD | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Missing | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Missing | 17 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-MD | 2 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Missing | 12 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-CR | 22 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Missing | 3 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-CR | 17 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-CR | 11 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Mod D | 1 Participants |
| Switched From CT-P13 to Remicade | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-CR | 24 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-CR | 43 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-MD | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-MD | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Mod D | 1 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-CR | 42 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Missing | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-Missing | 10 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | At Baseline | 49 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-CR | 28 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-MD | 2 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 6-MD | 4 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Missing | 19 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 24-Mod D | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Missing | 6 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 18-CR | 37 Participants |
| Multiple Switchers | Crohn's Disease: Number of Participants With Shift From Baseline in Harvey Bradshaw Index (HBI) According to Clinical Remission | Baseline-CR; Month 12-Mod D | 0 Participants |
Secondary
Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24
C-reactive protein (CRP) was a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. A decrease in the level of CRP indicated reduction in inflammation and therefore improvement.
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS=all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes (clinical assessment of disease activity, laboratory and imaging results related to treatment or assessment of CD or UC). Here, Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 18 | -6.57 milligram per liter (mg/L) | Standard Deviation 45.2 |
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Baseline | 13.70 milligram per liter (mg/L) | Standard Deviation 43.8 |
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 24 | 0.33 milligram per liter (mg/L) | Standard Deviation 177.3 |
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 6 | -1.09 milligram per liter (mg/L) | Standard Deviation 47.4 |
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 12 | -4.87 milligram per liter (mg/L) | Standard Deviation 38.6 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 18 | 0.63 milligram per liter (mg/L) | Standard Deviation 37.7 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 12 | -2.23 milligram per liter (mg/L) | Standard Deviation 17.3 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 6 | 1.46 milligram per liter (mg/L) | Standard Deviation 40 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 24 | -3.51 milligram per liter (mg/L) | Standard Deviation 18.2 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Baseline | 10.23 milligram per liter (mg/L) | Standard Deviation 22.6 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 12 | -1.62 milligram per liter (mg/L) | Standard Deviation 12.2 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Baseline | 8.79 milligram per liter (mg/L) | Standard Deviation 17 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 6 | -1.45 milligram per liter (mg/L) | Standard Deviation 14.6 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 18 | -2.45 milligram per liter (mg/L) | Standard Deviation 11.7 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 24 | 3.19 milligram per liter (mg/L) | Standard Deviation 41.7 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 24 | 4.17 milligram per liter (mg/L) | Standard Deviation 24.6 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Baseline | 7.70 milligram per liter (mg/L) | Standard Deviation 11.8 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 18 | 1.83 milligram per liter (mg/L) | Standard Deviation 12.6 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 12 | 3.88 milligram per liter (mg/L) | Standard Deviation 25.4 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 6 | -1.88 milligram per liter (mg/L) | Standard Deviation 12.3 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 12 | -4.84 milligram per liter (mg/L) | Standard Deviation 30.7 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 18 | -0.59 milligram per liter (mg/L) | Standard Deviation 51.8 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Baseline | 12.18 milligram per liter (mg/L) | Standard Deviation 30.7 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 24 | -3.11 milligram per liter (mg/L) | Standard Deviation 19.6 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: C-Reactive Protein at Months 6, 12, 18, and 24 | Change at Month 6 | 0.94 milligram per liter (mg/L) | Standard Deviation 32.8 |
Secondary
Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24
Here, the laboratory tests related to the treatment or assessment of Crohn's Disease or Ulcerative Colitis was fecal calprotectin.
Time frame: Baseline, Months 6, 12, 18, and 24
Population: FAS=all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes (clinical assessment of disease activity, laboratory and imaging results related to treatment or assessment of CD or UC). Here, Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 18 | -473.07 milligram per kilogram (mg/kg) | Standard Deviation 1394.3 |
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Baseline | 1066.31 milligram per kilogram (mg/kg) | Standard Deviation 5419.8 |
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 24 | -625.69 milligram per kilogram (mg/kg) | Standard Deviation 1684.7 |
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 6 | -283.21 milligram per kilogram (mg/kg) | Standard Deviation 989 |
| CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 12 | -165.32 milligram per kilogram (mg/kg) | Standard Deviation 691.9 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 18 | 275.48 milligram per kilogram (mg/kg) | Standard Deviation 1518 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 12 | 361.51 milligram per kilogram (mg/kg) | Standard Deviation 1741.1 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 6 | -296.95 milligram per kilogram (mg/kg) | Standard Deviation 958.1 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 24 | -862.40 milligram per kilogram (mg/kg) | Standard Deviation 958.4 |
| Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Baseline | 556.88 milligram per kilogram (mg/kg) | Standard Deviation 916.2 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 12 | -289.57 milligram per kilogram (mg/kg) | Standard Deviation 1004.9 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Baseline | 362.48 milligram per kilogram (mg/kg) | Standard Deviation 642.8 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 6 | -164.60 milligram per kilogram (mg/kg) | Standard Deviation 440.8 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 18 | 88.44 milligram per kilogram (mg/kg) | Standard Deviation 746.8 |
| Switched From Remicade to CT-P13 | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 24 | -494.66 milligram per kilogram (mg/kg) | Standard Deviation 1226.4 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 24 | -13.35 milligram per kilogram (mg/kg) | Standard Deviation 273.4 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Baseline | 616.03 milligram per kilogram (mg/kg) | Standard Deviation 1023.3 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 18 | -73.94 milligram per kilogram (mg/kg) | Standard Deviation 125.3 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 12 | -382.73 milligram per kilogram (mg/kg) | Standard Deviation 503.1 |
| Switched From CT-P13 to Remicade | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 6 | -648.16 milligram per kilogram (mg/kg) | Standard Deviation 1333.1 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 12 | -643.67 milligram per kilogram (mg/kg) | Standard Deviation 2339.3 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 18 | 109.16 milligram per kilogram (mg/kg) | Standard Deviation 164.4 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Baseline | 537.58 milligram per kilogram (mg/kg) | Standard Deviation 1471.9 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 24 | -450.98 milligram per kilogram (mg/kg) | Standard Deviation 200.2 |
| Multiple Switchers | Mean Change From Baseline in Laboratory Test Results: Fecal Calprotectin at Months 6, 12, 18, and 24 | Change at Month 6 | 224.56 milligram per kilogram (mg/kg) | Standard Deviation 700.1 |
Secondary
Number of Participants Remaining in Clinical Remission or Relapse
Clinical remission in participants was defined by a total Mayo score of 2 points or lower, with no individual sub score exceeding 1 point. Mayo score is an instrument designed to measure disease activity. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of centrally read flexible proctosigmoidoscopy and physician's global assessment, each sub score graded from 0 to 3 with higher scores indicating more severe disease. These scores were summed up to give a total score range of 0 to 12; where higher scores indicating more severe disease. The relapse of clinical remission was defined as the time from the date of first attaining CR to the date of relapse or death from any cause, whichever occurred first.
Time frame: Months 6, 12, 18 and 24
Population: Full analysis set (FAS)=all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes (clinical assessment of disease activity, laboratory and imaging results related to assessment of CD or UC).Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Relapse | 166 Participants |
| CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Relapse | 112 Participants |
| CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Remission | 802 Participants |
| CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Remission | 386 Participants |
| CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Relapse | 38 Participants |
| CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Relapse | 70 Participants |
| CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Remission | 870 Participants |
| CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Remission | 633 Participants |
| Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Relapse | 7 Participants |
| Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Remission | 184 Participants |
| Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Relapse | 23 Participants |
| Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Remission | 312 Participants |
| Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Remission | 288 Participants |
| Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Remission | 257 Participants |
| Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Relapse | 11 Participants |
| Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Relapse | 18 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Relapse | 16 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Relapse | 9 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Relapse | 11 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Relapse | 19 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Remission | 148 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Remission | 192 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Remission | 224 Participants |
| Switched From Remicade to CT-P13 | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Remission | 261 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Remission | 45 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Relapse | 2 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Remission | 51 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Relapse | 1 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Remission | 31 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Relapse | 1 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Relapse | 3 Participants |
| Switched From CT-P13 to Remicade | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Remission | 23 Participants |
| Multiple Switchers | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Remission | 39 Participants |
| Multiple Switchers | Number of Participants Remaining in Clinical Remission or Relapse | Month 24 | Relapse | 4 Participants |
| Multiple Switchers | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Remission | 70 Participants |
| Multiple Switchers | Number of Participants Remaining in Clinical Remission or Relapse | Month 6 | Relapse | 4 Participants |
| Multiple Switchers | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Remission | 58 Participants |
| Multiple Switchers | Number of Participants Remaining in Clinical Remission or Relapse | Month 12 | Relapse | 6 Participants |
| Multiple Switchers | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Remission | 61 Participants |
| Multiple Switchers | Number of Participants Remaining in Clinical Remission or Relapse | Month 18 | Relapse | 5 Participants |
Secondary
Number of Participants With Imaging Test Results
Number of participants who had Imaging test results related to the treatment or assessment of Crohn's Disease or Ulcerative Colitis were reported.
Time frame: From baseline up to follow-up period (a maximum of 2 years)
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes (clinical assessment of disease activity, laboratory and imaging results related to treatment or assessment of CD or UC).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CT-P13 | Number of Participants With Imaging Test Results | 516 Participants |
| Remicade | Number of Participants With Imaging Test Results | 134 Participants |
| Switched From Remicade to CT-P13 | Number of Participants With Imaging Test Results | 106 Participants |
| Switched From CT-P13 to Remicade | Number of Participants With Imaging Test Results | 28 Participants |
| Multiple Switchers | Number of Participants With Imaging Test Results | 50 Participants |
Secondary
Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent
The Montreal classification index for Ulcerative Colitis (UC) was used to classify the extent and severity of the disease activity. There were three subgroups of UC defined by extent: Extent 1 (E1) =Ulcerative proctitis, Extent 2 (E2) =Left-sided UC and Extent 3 (E3) =Extensive UC.
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E1 Ulcerative proctitis | 41 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E1 Ulcerative proctitis | 15 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E3 Extensive UC | 59 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | Missing | 3 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E3 Extensive UC | 128 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E2 Left-sided UC | 151 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E2 Left-sided UC | 76 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E1 Ulcerative proctitis | 31 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | Missing | 0 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E3 Extensive UC | 96 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E3 Extensive UC | 188 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E3 Extensive UC | 159 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | Missing | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E1 Ulcerative proctitis | 17 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | Missing | 3 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E1 Ulcerative proctitis | 14 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E2 Left-sided UC | 55 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E2 Left-sided UC | 26 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | Missing | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E2 Left-sided UC | 109 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E2 Left-sided UC | 23 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E1 Ulcerative proctitis | 5 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E2 Left-sided UC | 21 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | Missing | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E3 Extensive UC | 37 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | Missing | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | Missing | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E1 Ulcerative proctitis | 10 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E2 Left-sided UC | 10 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E3 Extensive UC | 29 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E2 Left-sided UC | 26 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E3 Extensive UC | 50 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | Missing | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E2 Left-sided UC | 16 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E1 Ulcerative proctitis | 9 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E1 Ulcerative proctitis | 7 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E3 Extensive UC | 15 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E3 Extensive UC | 40 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | Missing | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E1 Ulcerative proctitis | 7 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E2 Left-sided UC | 30 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E1 Ulcerative proctitis | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E1 Ulcerative proctitis | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E3 Extensive UC | 18 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E1 Ulcerative proctitis | 4 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E2 Left-sided UC | 24 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E3 Extensive UC | 21 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E2 Left-sided UC | 13 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E3 Extensive UC | 25 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E3 Extensive UC | 31 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E1 Ulcerative proctitis | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E2 Left-sided UC | 12 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E2 Left-sided UC | 8 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E3 Extensive UC | 15 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E1 Ulcerative proctitis | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E1 Ulcerative proctitis | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E1 Ulcerative proctitis | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E2 Left-sided UC | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E3 Extensive UC | 4 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E1 Ulcerative proctitis | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E2 Left-sided UC | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E3 Extensive UC | 13 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E1 Ulcerative proctitis | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E2 Left-sided UC | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E3 Extensive UC | 12 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E2 Left-sided UC | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E3 Extensive UC | 11 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E1 Ulcerative proctitis | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E2 Left-sided UC | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E3 Extensive UC | 7 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E3 Extensive UC | 13 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E2 Left-sided UC | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E1 Ulcerative proctitis | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E2 Left-sided UC | 6 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E3 Extensive UC | 12 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E1 Ulcerative proctitis | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E2 Left-sided UC | 5 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E2 Left-sided UC | 8 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Baseline | E1 Ulcerative proctitis | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 6 | E1 Ulcerative proctitis | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 18 | E3 Extensive UC | 10 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E3 Extensive UC | 10 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E2 Left-sided UC | 7 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 24 | E3 Extensive UC | 9 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Extent | Month 12 | E1 Ulcerative proctitis | 1 Participants |
Secondary
Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity
The Montreal classification index for UC was used to classify the extent and severity of the disease activity. UC can be classified broadly into four disease activity/severity categories: Severity 0 (S0) = asymptomatic clinical remission; Severity 1 (S1) = Mild UC (passage of four or fewer stools/day \[with or without blood\], absence of any systemic illness, and normal inflammatory markers); Severity 2 (S2) = Moderate UC (passage of more than four stools per day but with minimal signs of systemic toxicity) and Severity 3 (S3) = Severe UC (passage of at least six bloody stools daily).
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S0 | 122 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S3 | 11 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S2 | 12 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S3 | 75 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | Missing | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S1 | 70 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S0 | 81 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | Missing | 0 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S2 | 40 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S3 | 15 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S2 | 74 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S1 | 12 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | Missing | 3 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S1 | 58 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S2 | 29 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S3 | 32 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S1 | 75 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S3 | 6 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | Missing | 5 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S1 | 41 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | Missing | 4 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S0 | 71 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S2 | 147 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S0 | 80 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S0 | 110 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S0 | 35 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S0 | 39 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S2 | 14 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | Missing | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S1 | 16 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | Missing | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S3 | 3 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S2 | 6 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S2 | 3 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S3 | 9 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S1 | 6 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | Missing | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S0 | 20 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S0 | 40 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S1 | 17 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | Missing | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S1 | 19 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S0 | 46 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S3 | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S2 | 7 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S3 | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S2 | 5 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S3 | 5 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S1 | 11 Participants |
| Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | Missing | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S0 | 23 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S0 | 24 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S1 | 18 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S2 | 19 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S3 | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S0 | 26 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S1 | 15 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S2 | 6 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S3 | 3 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S0 | 25 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S1 | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S2 | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S3 | 3 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S1 | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S2 | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S3 | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S0 | 17 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S1 | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S2 | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S3 | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S2 | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S0 | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S3 | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S1 | 6 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S3 | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S0 | 6 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S1 | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S1 | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S3 | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S2 | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S3 | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S2 | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S1 | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S2 | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S0 | 9 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S3 | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S0 | 6 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S1 | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S2 | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S0 | 10 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S0 | 8 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S3 | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S1 | 4 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S2 | 3 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S2 | 4 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S1 | 9 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | S3 | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 6 | S0 | 7 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S3 | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 18 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S0 | 6 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S0 | 7 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S3 | 3 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S1 | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S2 | 9 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S2 | 4 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S1 | 8 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 24 | S2 | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S3 | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Month 12 | S0 | 6 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants Categorized on the Basis of Montreal Classification Index by Severity | Baseline | S1 | 4 Participants |
Secondary
Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission
Mayo Score is an instrument to measure disease activity of UC. Score ranges from 0 to 12 points. It consists of 4 sub scores, each graded from 0 to 3. Higher scores = more severe disease. A Partial Mayo Score (PMS) (Mayo score without endoscopy) is comprised of 3 parameters: stool frequency ranging from 0 (normal number of stools) to 3 (having \>=5 stools more than normal), the presence of rectal bleeding (ranging from 0=no blood seen to 3=blood alone passes), and physician's global assessment (ranging from 0=normal to 3=severe disease). The total partial Mayo score was the sum of all the parameters, score ranging from 0 (normal or inactive disease) to 9 (severe disease). Higher scores indicated more severe disease. The score was calculated if data were available for at least 1 of 3 Mayo sub scores. The level of disease activity was interpreted as clinical remission (CR) (PMS \<2), mild disease (MD) (PMS=2 to 4), moderate disease (Mod D) (PMS=5 to 6) and severe disease (SD) (PMS \>6).
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-SD | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-MD | 13 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-SD | 1 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Missing | 17 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-CR | 117 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Missing | 60 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Mod D | 5 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-MD | 24 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-SD | 1 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | At Baseline | 169 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-CR | 57 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Mod D | 6 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-CR | 88 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Mod D | 7 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Missing | 32 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-MD | 7 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Missing | 103 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-CR | 107 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-MD | 27 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Mod D | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-CR | 65 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Mod D | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | At Baseline | 83 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Missing | 39 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-MD | 4 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-MD | 8 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Missing | 14 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-CR | 65 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Missing | 9 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Missing | 20 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-CR | 38 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-MD | 9 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-MD | 5 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-CR | 55 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Missing | 14 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-CR | 25 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-MD | 4 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Mod D | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-SD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Missing | 23 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-CR | 22 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-MD | 3 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Missing | 29 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | At Baseline | 55 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-CR | 40 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-MD | 7 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-SD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Missing | 6 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-CR | 30 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-MD | 10 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Mod D | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-CR | 7 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-MD | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Missing | 6 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Missing | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-CR | 8 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Missing | 6 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | At Baseline | 9 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Mod D | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-MD | 4 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Missing | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-CR | 9 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-MD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-CR | 6 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-MD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-MD | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Missing | 7 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Missing | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | At Baseline | 13 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-CR | 8 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-Mod D | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-CR | 9 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 12-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 6-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 24-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Clinical Remission | Baseline-CR; Month 18-Mod D | 3 Participants |
Secondary
Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity
Mayo Score is an instrument to measure disease activity of UC. Score ranges from 0 to 12 points. It consists of 4 sub scores, each graded from 0 to 3. Higher scores= more severe disease. A Partial Mayo Score (PMS) (Mayo score without endoscopy) is comprised of 3 parameters: stool frequency ranging from 0 (normal number of stools) to 3 (having \>=5 stools more than normal), the presence of rectal bleeding ranging from 0 (no blood seen) to 3 (blood alone passes), and physician's global assessment ranging from 0 (normal) to 3 (severe disease). The total partial Mayo score was the sum of all the parameters, score ranging from 0 (normal or inactive disease) to 9 (severe disease). Higher scores indicated more severe disease. The score was calculated if data were available for at least 1 of 3 Mayo sub scores. The level of disease activity was interpreted as clinical remission (CR) (PMS \<2), mild disease (MD) (PMS=2 to 4), moderate disease (Mod D) (PMS=5 to 6) and severe disease (SD) (PMS \>6).
Time frame: Baseline, Months 6, 12, 18 and 24
Population: FAS =all participants who received at least 1 dose of study drug and had at least one post-dose assessment of any of the effectiveness outcomes. Here, Overall number of participants analyzed =Number of participants evaluable for this outcome measure. Number analyzed =participants evaluable at specified time points for each arm.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-SD | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Mod D | 5 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-CR | 8 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Missing | 13 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Mod D | 1 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-MD | 8 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-MD | 10 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-MD | 19 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Missing | 68 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-CR | 71 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-SD | 7 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-CR | 43 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Mod D | 6 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 1 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-CR | 18 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-SD | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Missing | 24 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-SD | 7 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Missing | 30 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-CR | 57 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Missing | 7 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-MD | 11 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-MD | 22 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Mod D | 5 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Mod D | 3 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-CR | 73 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: SD | 47 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-MD | 8 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Mod D | 8 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-MD | 5 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-MD | 38 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-CR | 15 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-MD | 48 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 21 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-CR | 15 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Mod D | 10 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-CR | 15 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Missing | 27 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Missing | 17 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Missing | 35 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-SD | 3 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Missing | 99 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: Mod D | 76 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-SD | 8 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Missing | 33 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-SD | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Missing | 47 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: MD | 157 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-CR | 24 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-CR | 8 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Missing | 7 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-MD | 16 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-MD | 17 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-SD | 2 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Mod D | 18 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-MD | 22 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-CR | 23 Participants |
| CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 6 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Missing | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Mod D | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Missing | 10 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: Mod D | 13 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Missing | 4 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Missing | 7 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Mod D | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-CR | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-MD | 5 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-MD | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-CR | 14 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Missing | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: MD | 30 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-SD | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Missing | 4 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-CR | 3 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-MD | 3 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-MD | 8 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-CR | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: SD | 5 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Missing | 12 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-SD | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Missing | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Missing | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Mod D | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-CR | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-MD | 4 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-MD | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-CR | 13 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-CR | 12 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Missing | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-MD | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Mod D | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-CR | 16 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-MD | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-MD | 6 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-CR | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Mod D | 3 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-MD | 12 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Missing | 6 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Missing | 5 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-CR | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 1 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-CR | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-MD | 2 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-MD | 6 Participants |
| Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-CR | 4 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: MD | 28 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: Mod D | 9 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: SD | 3 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-CR | 19 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-MD | 4 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-SD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Missing | 3 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-CR | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-MD | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Missing | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-CR | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-MD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-SD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-CR | 14 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-MD | 7 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-SD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Missing | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-CR | 4 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-MD | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Missing | 3 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-CR | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-MD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Mod D | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-CR | 15 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-MD | 6 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Missing | 6 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-CR | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-MD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Missing | 5 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-CR | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-MD | 2 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Mod D | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Missing | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-CR | 13 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-MD | 3 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Missing | 11 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-CR | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-MD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-SD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Missing | 7 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-CR | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-MD | 1 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| Switched From Remicade to CT-P13 | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Missing | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-CR | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Missing | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: MD | 4 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-CR | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: Mod D | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Missing | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-CR | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-CR | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-MD | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-CR | 2 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-MD | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Missing | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-CR | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Missing | 3 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-SD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-MD | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-SD | 1 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Missing | 0 Participants |
| Switched From CT-P13 to Remicade | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Missing | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: Mod D | 4 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-MD | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-MD | 6 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-CR | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-CR | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-MD | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Missing | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: MD | 9 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-Mod D | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-CR | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 18-Missing | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-MD | 5 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-CR | 3 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-CR | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 12-CR | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-MD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-MD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 18-Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-MD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | At Baseline: SD | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-CR | 5 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 6-CR | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-MD | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Missing | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 24-Missing | 3 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-MD | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Missing | 3 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-CR | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 6-CR | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-MD | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-Missing | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-MD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 6-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-CR | 3 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 12-CR | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-MD | 2 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Missing | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-SD; Month 24-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-Mod D | 1 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-MD; Month 18-SD | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 12-Mod D | 0 Participants |
| Multiple Switchers | Ulcerative Colitis: Number of Participants With Shift From Baseline in Partial Mayo Scoring System According to Disease Activity | Baseline-Mod D; Month 24-Missing | 1 Participants |